Our Patient Advocate, Jessica Behrend, RN, MSN, FNP-BC, shares more about her experience working with people with #Cushing’s Syndrome here: https://bit.ly/4cGYBHt #CushingsSyndrome #endocrinology #hypercortisolism
Corcept Therapeutics
Biotechnology Research
Menlo Park, CA 34,488 followers
Pioneering the discovery and development of cortisol modulators.
About us
At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept.
- Website
-
http://www.corcept.com
External link for Corcept Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Menlo Park, CA
- Type
- Public Company
- Founded
- 1998
Locations
-
Primary
149 Commonwealth Dr
Menlo Park, CA 94025, US
Employees at Corcept Therapeutics
Updates
-
Our CATALYST trial examined the prevalence of #hypercortisolism among people with difficult-to-control type 2 #diabetes. Learn more in this article from Patrick Campbell at HCPLive: https://lnkd.in/gmFDQYF8 #ADA2024 #ADAScientificSessions #T2D
-
What began as a ripple of scientific truth is poised to unleash a sea change of discovery. Learn how: https://www.corcept.com/ #CortisolModulation #endocrinology #oncology #metabolism #neurology
-
Final results from the prevalence phase of our phase IV clinical trial study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented today at the American Diabetes Association 84th Scientific Sessions. Read more: https://lnkd.in/g_SbwHCT #CortisolModulation #Diabetes #Type2Diabetes #ADASciSessions #Hypercortisolism
-
Today at ADA our CATALYST data are being presented in the session: ADA Catalyst Plenary - Prevalence of Hypercortisolism in Difficult to Control Type 2 Diabetes. We look forward to the insightful discussion, which will be held in W415B (Valencia Ballroom) from 3:15pm – 4:15pm EDT. American Diabetes Association #CortisolModulation #Diabetes #ADASciSessions #Hypercortisolism
-
Are you driven by the idea of working in a scientific environment that offers both independence and open collaboration? Join us as we follow the data to unlock the potential of cortisol modulation to treat serious diseases. https://bit.ly/3V4V5PX #CortisolModulation #Endocrinology #Oncology
-
We are delighted to introduce our 2024 Summer Intern class! They bring a wide array of educational expertise including studies in law, finance, data science, economics, biology, psychology, biochemistry, and engineering. We eagerly welcome their enthusiasm and innovative ideas as they lead initiatives across several functions and departments in the organization. Join us in welcoming them to the Corcept team!
-
You’ll find us this week at the American Diabetes Association’s 84th Scientific Sessions in Orlando! Visit us at booth #401. #CortisolModulation #Diabetes #ADASciSessions
This content isn’t available here
Access this content and more in the LinkedIn app
-
Today at the 8th annual Heart in Diabetes we’re sharing more information about our GRACE clinical trial data in our presentation: Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study. Metabolic Endocrine Education Foundation #CortisolModulation #8thHeartinDiabetes #HID2024
-
Highlighting contributions from scientists who identify as LGBTQ+ not only breaks stereotypes but also provides crucial role models for future generations, promoting inclusivity and innovation in scientific communities. To honor #PrideMonth, Corcept celebrates the work of Dr. Neena Schwartz, an endocrinologist who identified as a lesbian. Learn more about her life here: https://bit.ly/3x0mY3D